The FBI director, IRS commissioner and vice chair of the Federal Reserve, all criticized by Republicans, have opted to resign instead of staying in their jobs, which have terms designed to straddle presidential administrations.

The Federal Reserve now needs to be on Trump watch if it wants to engineer the proper dose of monetary policy, according to Bank of America chief Brian Moynihan. "They've got a new administration with a new set of fiscal policies,

Trump is a man in a hurry, and social media is buzzing with questions about whether he will fulfill his promise of a strategic Bitcoin reserve.

Trump will probably seek to ease inflation and lower prices by drilling for more oil, loosening regulations, reducing federal spending, experts say.

CNBC's Jim Cramer on Wednesday told investors there will be a shift in Wall Street's focus, from the actions of the Federal Reserve to those of President Donald Trump. "We're now looking at the changing of the guard from Powell to Trump,

President Donald Trump doesn’t like to wait, and patience is exactly what the Federal Reserve is serving right now. After December’s strong jobs report, the Fed seems comfortable sitting tight, keeping interest rates steady instead of cutting them.

President Donald Trump wasted no time in getting to work on his first day in office with a range of executive orders, but the fiscal house he’s inheriting may prove more challenging to fix.

Investors considering alternative strategies should proactively adjust their portfolios to anticipate these potential changes.

Several large U.S. financial institutions, including the Federal Reserve, have withdrawn from the networks after years of growing political and legal pressure.

President Donald Trump began his second administration with a blitz of policy actions to reorient U.S. government priorities

Trump's VA pick, former Rep. Doug Collins, said the VA may be trying to fill positions, but many of those vacancies have gone unfilled for weeks or longer.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.